Back to Journals » Research and Reports in Urology » Volume 5
Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
Authors Lee R, Bamberger M, Ellsworth P
Received 1 August 2013
Accepted for publication 5 September 2013
Published 25 October 2013 Volume 2013:5 Pages 147—157
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Raymond T Lee,1 Mitchell Bamberger,2 Pamela Ellsworth3
1University of Massachusetts Medical School, 2UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, 3Division of Urology/Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USA
Abstract: Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory efficacy and/or tolerability. Mirabegron is the first beta-3 adrenoceptor agonist approved for the treatment of overactive bladder syndrome. This paper reviews the pharmacology, mechanism of action, efficacy, and safety of mirabegron. A PubMed search of all English articles pertaining to mirabegron was performed. An alternative to antimuscarinics, mirabegron has a unique mechanism, improves overactive bladder symptoms and quality of life, and has limited adverse effects and few contraindications.
Keywords: overactive bladder, incontinence, beta-3 agonist, mirabegron
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.